An epidemiologic analysis of co-occurring alcohol and drug use and disorders: findings from the National Epidemiologic Survey of Alcohol and Related Conditions (NESARC).

The 2001-2002 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) sought to determine the prevalence of alcohol use and alcohol use disorders (AUDs), other drug use and drug use disorders (DUDs), and co-use and co-morbidity in the general adult U.S. population. Findings indicate that 5.6 percent of U.S. adults used both alcohol and drugs in the past year and that 1.1 percent had a co-morbid AUD and DUD. Alcohol use prevalence peaked between the ages of 25 and 44 and declined thereafter. The prevalence of other drug use, co-use, AUDs, DUDs, and co-morbid disorders was highest between the ages of 18 and 24 and declined steadily thereafter. Women and men showed similar trends for alcohol use, drug use, and co-use. Among ethnic/racial groups evaluated, Whites displayed the highest rates of alcohol use and American Indians/Alaskan Natives the highest rates of drug use. For AUDs, DUDs, and co-morbid disorders, rates were highest among American Indians/Alaskan Natives. The prevalence of drug use, weekly drug use, and DUDs increased with increasing levels of alcohol consumption and the presence of AUDs. The proportion of people with AUDs who had a co-morbid DUD varied considerably by drug type. These findings have important implications for the development of prevention and intervention approaches.

• Heterotypic co-morbidity, which refers to the co-occurrence of disorders hol use disor N umerous epidemiological studies (Grant et al. 2004) have demonstrated that alcoders (AUDs) (i.e., alcohol abuse and alcohol dependence) are widespread in the general population of the United States, with approximately 8.5 percent of adults having had an AUD in the past year. Importantly, many people suffering from AUDs also suffer from one or more other psychiatric disorders, including other drug use disorders (DUDs), mood disorders (e.g., major depression), anxiety disorders, or personality disorders (e.g., antisocial personal ity disorder). This co-morbidity has important implications for diagnosis and, particularly, therapy because people from different diagnostic groupings, such as the co-occurrence of an AUD with a mood or anxiety disorder.
Over the past two to three decades, researchers have intensely studied the relationships between AUDs and het erotypic psychiatric disorders to deter mine the prevalence and underlying causes of the co-morbidity (for a review, see Petrakis et al. 2002). Much less is known about the homotypic co morbidity of AUDs and DUDs, the potential causes or mechanisms under lying this co-morbidity, and its impact on treatment seeking and treatment outcome. The existing studies nonethe less have provided valuable information on homotypic co-morbidity.
Some of this research has focused on the possible mechanisms underly ing the concurrent use of alcohol and other drugs. For example, researchers have investigated the possibility of genetic and environmental risk factors that may account for part of the observed association. (For more infor mation, see the article by Dick and Agrawal, Other stud ies have examined the neurobiological aspects of co-morbid alcohol and other drug use, seeking to identify shared mechanisms through which the different drug classes may act on the brain. (For more information, see the article by Cruz et al., Although these avenues of research are of the utmost importance, it is equally critical to obtain a solid understanding of the scope of the problem. Thus, it is important to know the rates of AUDs, DUDs, and co-morbid disorders in the general population and whether certain demographic subgroups are particu larly at risk of having both disorders. To date, however, only a handful of large epidemiological studies (Burns and Teesson 2002;Grant and Pickering 1996;Helzer and Pryzbeck 1988;Kessler et al. 1997;Regier et al. 1990;Ross 1995;Stinson et al. 2005) have investigated the prevalence of AUD and DUD co-morbidity in the gener al population. In general, these stud ies found that between 13 and 17 percent of individuals with a past-year AUD also had a co-morbid pastyear DUD. On a lifetime basis, the co-morbidity rates are higher. For instance, among individuals with a lifetime AUD, rates of a lifetime DUD ranged from 20 to 23 percent. Further more, lifetime co-morbid DUD rates were relatively higher among respon dents with alcohol dependence than among those who abuse alcohol (Kessler et al. 1997;Ross 1995) and among women than men (Kessler et al. 1997).
It is important to know the rates of AUDs, DUDs, and co-morbid disorders in the general population and whether certain demographic subgroups are particularly at risk of having both disorders.
Thus, these studies have demon strated that AUDs and DUDs are quite likely to co-occur. However, despite this important insight, these studies suffer from several drawbacks that make it difficult to accurately determine the extent of co-morbidity. First, all but a few of the studies (Burns and Teeson 2002;Stinson et al. 2005) reported prevalence of alcohol and other drug use and/or co-morbidity on a lifetime basis rather than on a current (i.e., 12 month) basis. Data derived from life time diagnoses, however, produce larger co-morbidity estimates than data derived from past-year estimates. This is because lifetime co-morbid diag noses include additional cases in which AUDs and DUDs were not present contemporaneously but rather may have been separated by a considerable time gap, even several years apart. 1 Second, with a few exceptions (Grant and Pickering 1996;Helzer and Pryzbeck 1988;Stinson et al. 2005), most co-morbidity studies have not systematically compared the prevalence of drug-specific DUDs among people with an AUD. Disaggregation of the DUDs into specific types (e.g., cannabis, cocaine, opioids, heroin, and prescription medications), however, is warranted because the prevalence of specific DUDs has been shown to vary greatly among the population of people with comorbidities as well as in the general population (Stinson et al. 2005).
Third, most of the existing co morbidity analyses did not present information on broader alcohol and drug co-use, which also includes peo ple who do not meet the diagnostic criteria of an AUD or DUD. A few recent epidemiological studies have examined the extended scope of co use in the United States. These stud ies generally have focused on co-use of one class of drugs, such as cannabis use (Degenhardt and Hall 2003), rather than presenting data that include all types of drug use. Despite this restricted focus, data from these studies have suggested an interest ing dose-response relationship between increasing levels of alcohol consump tion and the increased prevalence of specific types of drug use.
In a recent study, Stinson and col leagues (2005), using data from the 2001-2002 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), described the rates of drug-specific disorders among individuals with AUDs as well as sociodemographic characteristics associated with co-morbid AUDs and DUDs. The present article expands on this work by Stinson and col leagues (2005) and fills some gaps in previous studies. The main objective is to present detailed epidemiologic information on the prevalence of homotypic alcohol and drug co-use and co-morbidity in the U.S. adult population. The analysis is based on comprehensive definitions of drug use and DUDs and includes separate analyses for 10 classes of drugs, with most prevalence estimates presented by gender, age, and race/ethnicity. In addition, this study explores how the prevalence of drug use and DUDs varies with levels of alcohol consumption and the presence of AUDs. Also, rates of drug-specific drug use and DUDs among adults with AUDs are provided.

Data
The present study is based on data from the first wave of NESARC, con ducted by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) in [2001][2002]. NESARC is among the largest nationally representative co morbidity surveys ever conducted and includes extensive questions on alcohol and drug use and related disorders. The NESARC sample includes 43,093 respondents ages 18 and older, repre senting the civilian, noninstitutional ized adult population of the United States, including residents of all 50 States and the District of Columbia. Military personnel living off base and persons living in noninstitutionalized group-quarter housing, such as board ing houses, shelters, and dormitories, also were included (Grant et al. 2003

Measures
Alcohol Measures. All alcohol mea sures employed in the present analysis reflect consumption and diagnostic status during the past year (i.e., the 12 months preceding the time of the NESARC interview). Although NESARC collected alcohol data sepa rately for each of four beverage types (i.e., wine, beer, coolers, and distilled spirits), the results presented here are the aggregate across beverage types. The various alcohol measures are defined as follows: • Lifetime abstainer-Never had one or more drinks of alcohol during the course of a lifetime, excluding small tastes or sips.
• Former drinker-Had at least one drink prior to the past year but no drinks during the past year.
• Current drinker (or alcohol user)-Had at least one drink of alcohol dur ing the past year.
Based on past-year consumption, current drinkers are divided into three drinking levels: 2 -Light drinker-Had three or fewer drinks per week.
-Moderate drinker-Had 4-14 drinks per week for men and 4-7 drinks per week for women.
-Heavy drinker-Had more than 14 drinks per week for men and more than 7 drinks per week for women. -Alcohol abuse-Met at least one of the following four criteria for DSM-IV alcohol abuse (and did not meet criteria for alcohol dependence): continued use despite social or interpersonal conse quences, hazardous use, alcoholrelated legal consequences, or neglect of role responsibilities in favor of drinking.
-Alcohol dependence-Met at least three of the following seven criteria for DSM-IV alcohol dependence in the same 12-month period: toler ance, withdrawal syndrome or drinking to relieve/ avoid withdrawal, impaired control over drinking, persistent desire or unsuccessful attempts to cut down or stop drink ing, much time spent drinking, reducing/giving up important activities in favor of drinking, and continued drinking despite physical or psychological problems caused by drinking.

Drug Measures.
Like the alcohol measures above, the drug measures employed in the present study also reflect past-year use and diagnostic status. NESARC collected data separately for 10 classes of drugs: cannabis, cocaine (including crack cocaine), opioids 3 (other than heroin or methadone), hallucinogens, amphetamines, tranquilizers, seda tives, heroin, 4 inhalants/solvents, and other drugs. Note that nicotine was not included among these drug classes because the discussion in this article focuses on co-occurrence of alcohol use with illicit drug use. 5 The various drug measures are defined as follows: • Drug use-Had used at least 1 of the 10 classes of drugs during the past year.
• Weekly drug use-Had used at least 1 of the 10 classes of drugs during the past year at least once every week.
• DUD-Met DSM-IV criteria for drug abuse and/or drug dependence during the past year for at least 1 of the 10 classes of drugs. All drugspecific diagnoses of abuse and dependence were derived using the same algorithm and were aggregated to produce the measure of any DUD. DSM-IV criteria for the abuse and dependence of specific drugs are similar to those associated with alcohol. However, the with drawal syndrome, as part of the criteria for dependence, is only applicable to certain classes of drugs (i.e., sedatives, tranquilizers, opioids, amphetamines, and cocaine).

Co-Occurrence of Alcohol and Drug
Measures. Based on past-year alcohol and drug use and disorder status, two measures are defined: • Co-use-Had used both alcohol and drugs within the past year.
• Co-morbid-Had both an AUD and a DUD in the past year.

Data Analysis
Data presented in this article are descrip tive in nature. All prevalence estimates of alcohol and drug use and disorders are presented as percentages of the total adult population in the United States or of a subpopulation group. All analyses are carried out for men and women separately, except for rates of disorders by age and race/ethnicity, which are presented for both genders combined because of small sample sizes. Rates of

Prevalence of Alcohol and Drug Use and Co-Use
According to the NESARC data, approx imately 65 percent of adults in the United States used alcohol, whereas only about 6 percent used drugs during the past year (see table 1). Furthermore, almost 6 percent of adults used both alcohol and drugs, representing approximately 12.6 million adults in the U.S. popula tion. These data indicate that most drug users (approximately 90 percent) used alcohol, whereas only a small minority of alcohol users (less than 9 percent) used drugs. Although men and women had similar rates of using drugs only (0.7 and 0.6 percent, respectively 7 ), men were much more likely than women to use alcohol only (64.7 vs. 55.4 percent, respectively 8 ).
Moreover, men were more likely to use both alcohol and drugs, whereas women were more likely than men to abstain from both substances.
Prevalence by Age-Group. The preva lence of alcohol use by age-group showed a somewhat curvilinear pattern for both men and women (figure 1). Alcohol use already was common among people ages 18-24, with 6 The standard error is a measure of the precision of a given estimate and can be used to determine whether two estimates are significantly different from each other. It reflects the variability in the estimate that can be expected if multiple measurements are made on random samples drawn from the same population.
7 Derived from data in Table 1 by subtracting percent co use from percent any drug use.
8 Derived from data in Table 1 by subtracting percent co use from percent any alcohol use.  Relative standard error >0.30. The relative standard error is a measure of the unreliability of the prevalence estimate, calculated by dividing the standard error by the value of the prevalence estimate. A relative standard error >0.30 is not considered statistically reliable, and the prevalence estimate should be interpreted with caution. NOTE: The prevalence of "AUD only" and "DUD only" is derived as follows: % AUD only = % any alcohol use disorder -% co-use; % DUD = % any drug use disorder -% co-morbid. approximately 75 percent of men and approximately 67 percent of women in that age-group using alcohol. Alcohol use peaked at slightly higher levels at ages 25-44, began to decline among people ages 45-64, and was lowest among people ages 65 and older, among whom slightly more than half of men and slightly more than one-third of women used alcohol. In contrast, drug use declined monotonically with age for both gen ders, with the highest prevalence among the youngest group and the lowest prevalence among the oldest group. Because most drug users also used alcohol, the trajectory of co-use across age-groups is very similar to that of drug use-the highest rates were found among people ages 18-24 (almost one-fifth for men and oneeighth for women) and the lowest rate among people ages 65 and older (less than 1 percent for both genders).

Epidemiology of AOD Use and Disorders
Prevalence by Race/Ethnicity. The prevalence of alcohol use varied among racial/ethnic groups for both men and women. For both genders, Whites displayed the highest rates (about 75 percent for men and about 65 per cent for women) and Asians/Native Hawaiians/Pacific Islanders displayed the lowest rates (about 62 percent for men and about 36 percent for women). The prevalence of drug use for both genders was highest among American Indians/Alaskan Natives and lowest among Asian/Native Hawaiian/ Pacific Islander men and Hispanic women. Parallel to this pattern, the prevalence of using both alcohol and drugs was highest among American Indians/Alaskan Natives and lowest among Asian/Native Hawaiian/Pacific Islander men and Hispanic women. Whites, Blacks, and Hispanics had intermediate levels of co-use.

Prevalence of AUDs, DUDs, and Co-Morbidity
Approximately 8.5 percent of adults in the United States had an AUD and 2 percent had a DUD during the past year (table 2). Moreover, 1.1 percent of all adults had a co-morbid AUD and DUD, representing approximately 2.5 million adults. As with alcohol and drug use, these data indicate that more than half of people with a DUD also had an AUD, whereas only about one-eighth of people with an AUD had a DUD.
Prevalence by Gender. Men, com pared with women, had approximately 2.5 times higher rates of any AUD, any DUD, and co-morbid disorders (table 2) as well as AUDs only (10.7 vs. 4.3 percent, respectively 9 ). Men also had higher rates of DUDs only (1.1 vs. 0.7 percent, respectively 10 ).

Prevalence by Age-Group.
The preva lence of AUDs, DUDs, and co-morbid disorders decreased with age ( figure  2), with the highest rates (about 18 percent) found among the youngest 9 Derived from data in Table 2 by subtracting percent co use from percent any alcohol use.
10 Derived from data in Table 2 by subtracting percent co-use from percent any AUD.
group and the lowest rates found among the oldest group. 11 In terms of an absolute percentage decrease, the sharpest drop for all disorder cate gories occurred between the group of 18-to 24-year-old subjects and the group of 25-to 44-year-old subjects.

Prevalence by Race/Ethnicity. American
Indians/Alaskan Natives displayed the highest prevalence of AUDs, DUDs, and co-morbid disorders (about 12 percent, 5 percent, and 4 percent, respectively), and Asians/Native Hawaiians/Pacific Islanders had the lowest rates (4.5 percent, 1.4 percent, and 0.7 percent, respectively) (table 2). The rank ordering of DUDs gen erally followed that of AUDs, with the exception of Blacks, who had the second highest rate of DUDs, yet had almost the lowest rate of AUDs. Co morbidity rates generally displayed little variability across racial/ethnic groups, except for that of American Indians/ Alaskan Natives, which were significantly higher than those of the other groups.

Prevalence of Drug Use, Weekly Drug Use, and DUDs by Drinking Characteristics
NESARC data also demonstrate how drug use is related to the characteristics of alcohol consumption (i.e., lifetime abstainer; former drinker; light, moder ate, or heavy drinker; alcohol abuse; and alcohol dependence). For all three drug measures-any drug use, weekly drug use, and any DUD-the rates increased monotonically with increas ing levels of alcohol consumption and the presence of alcohol abuse and dependence (table 3, figures 3A-C). For instance, among both men and women, the prevalence of any drug use was lowest (i.e., around 1 percent) among lifetime alcohol abstainers, increased with levels of alcohol con sumption, and peaked among alcoholdependent people (about 43 percent for men and about 34 percent for women, respectively) (figure 3A). Similar positive trends also were observed between drinking characteris tics and weekly drug use (figure 3B) or any DUD ( figure 3C). The association between alcohol dependence and the three drug use measures was particu larly strong compared with the other drinking levels and alcohol abuse. For example, alcohol-dependent men and women had much higher prevalence of drug use than lifetime alcohol abstain ers, representing a 33 and 28 times increased risk for drug use, respectively.

Prevalence of Drug-Specific Drug Use and DUDs among Individuals with AUDs
Approximately 29 percent of people with AUDs also had used other drugs (table 4). However, this estimate varied considerably by drug type. For instance, cannabis use was by far the most commonly associated with AUDs (i.e., about one-quarter of cannabis users also had an AUD). The co-use of other drugs was less common, ranging from about 9.5 percent for opioids to less than 1 percent for inhalant/solvent, heroin, or other drugs. Few gender differences were apparent, except that cannabis use was more prevalent among men than women.
About one-eighth of people with an AUD also had a DUD (table 4). Similar to the pattern seen with drug use, rates of drug-specific DUDs var ied considerably by drug type, with the highest for cannabis (about 10 percent) and much lower ones for the rest of drugs. No notable gender differences were evident, except that co morbid cannabis use disorder was more prevalent among men than women.

Discussion and Conclusion
This study presents epidemiologic data on alcohol and drug co-use and co morbidity in the adult population of the United States. With approximately 12.6 million American adults having used both alcohol and other drugs in the past year, the extent of co-use is quite high. The number for co-morbid disorders is considerably lower, yet still sizable, with approximately 2.5 million American adults having both an AUD and a DUD. Consistent with other studies (Burns and Teeson 2002;Grant and Pickering 1996;Regier et al. 1990;Stinson et al. 2005), the prevalence of alcohol use and AUDs are much higher among people with drug use and DUDs, respectively, than vice versa. This reflects the fact that alcohol is much more widely used than other drugs. Also, as suggested by some studies, alcohol use may be a gateway to the use of illegal or more potent drugs (Wagner and Anthony 2002). Furthermore, higher rates of co-use and co-morbidity were found among certain demographic subgroups. For example, the current analysis revealed that the prevalence of co-use and co morbidity was higher in men than women. Moreover, the highest rates were seen in the youngest age-groups, with a steady decline observed in older age-groups. Among the racial/ ethnic subpopulations, American Indians/Alaskan Natives had the highest rates of alcohol and drug co-use and co-morbidity among both men and women. This last finding is particu larly important but rarely reported in the literature. Overall, the higher rates of co-use and co-morbidity found in these demographic subgroups were not surprising, given reports in the literature of higher rates of alco hol use, drug use, AUDs, and DUDs among these subpopulations (NIAAA 1998; Substance Abuse and Mental Health Services Administration [SAMSHA] 2007). Results from the current study suggest that prevention and treatment strategies for co-morbid alcohol and drug use disorders should place a special emphasis on men and focus efforts on other high-risk groups, such as young adults and American Indians/Alaskan Natives.
In addition to quantifying the cur rent rates of co-use and co-morbidity of alcohol and other drugs in the United States, the present study was unique in its investigation of the association between drinking charac teristics and any drug use and DUD. Results showed a dose-response rela tionship between the two classes of substances, with rates of drug use, weekly drug use, and DUDs increas ing monotonically with increasing levels of alcohol consumption and the presence of AUDs. This doseresponse relationship is consistent with studies that have examined spe cific classes of drugs. McCabe and colleagues (2006), using NESARC, found that the prevalence of any past-year prescription drug use (i.e., opioid, sedative, tranquilizer, or stim ulant use) was lowest among pastyear alcohol abstainers (about 1 per cent) and increased to approximately 2 percent among non-binge drinkers (without an AUD), 4 percent among binge drinkers (without an AUD), 8 percent among alcohol abusers, and 22 percent among those with alcohol dependence. Similarly, in a nationally representative Australian study, Degenhardt and Hall (2003) reported that the prevalence of past-year cannabis use increased monotonically by drinking levels, ranging from approximately 2 percent among pastyear abstainers to 7 percent among non-AUD drinkers, 27 percent among alcohol abusers, and 32 per cent among those with alcohol dependence. In addition, Degenhardt and Hall documented that the rates of past-year cannabis use disorders increased monotonically-ranging from 1 percent to 2, 11, and 15 per cent, respectively, for these groups. Furthermore, the findings from the current study are consistent with ear lier studies that looked at DUDs in general by AUDs. For example, Kessler and colleagues (1997) and Ross (1995) reported a substantially higher prevalence of DUDs among people with alcohol dependence than people who abuse alcohol.
The present study reproduced find ings first presented by Stinson and colleagues (2005) that documented the prevalence of specific DUDs among people with AUDs. These findings indicated that cannabis use disorder was by far the most fre quently occurring co-morbid DUD (10 percent), followed by cocaine and opioid use disorders (approximately 2.5 percent and 2.4 percent respec tively) and other DUDs (less than 2 percent). Thus, results referring to "any DUD co-morbidity," as present ed in the present study, are dispro portionately reflective of cannabis use disorder, as opposed to other co-mor bid DUDs. The magnitudes of these specific co-morbidity rates are similar to those found in a recent study that used data from the Australian National Survey of Mental Health and Well Being (Burns and Teeson 2002). In addition to the aforemen tioned studies, the present study was unique in its examination of how rates of specific co-morbid DUDs vary by gender. These results revealed few gender differences, with the exception of higher rates of co-mor bid cannabis use disorder among men than women. The present study also expanded upon the work of Stinson and colleagues (2005) by presenting rates of drug-specific drug use among adults with AUDs. Similar to the pat tern seen with drug-specific DUDs, cannabis was the drug most frequent ly used among people with AUDs (approximately 23 percent).
Thus, the prevalence estimates pre sented in this study provide health care policymakers and treatment planners with a comprehensive assess ment of the state of the use, co-use, and co-morbidity of alcohol and other drugs in the United States. Nonetheless, the current study is descriptive in nature. Given the high rates of co-use and co-morbidity in this country, continued research into the mechanisms underlying co-use and co-morbidity certainly are warranted. ■